Lupin launches Molnulup for COVID-19 treatment
Drugmaker Lupin on Friday said it has launched antiviral medication Molnupiravir under the brand name Molnulup in the country for the treatment of COVID-19. Molnupiravir has been given emergency use authorisation by the Drug Controller General of India (DCGI) for treatment of adult COVID-19 patients who have a high risk of progression of the disease, including hospitalisation. “The approval for Molnulup is timely as India is again experiencing an upward spike in COVID-19 incidences. In the past two years since COVID-19 has emerged, there is a need for an oral…
Read More